消風(fēng)散加減方聯(lián)合依巴斯汀治療風(fēng)熱犯表型蕁麻疹的臨床觀察
發(fā)布時(shí)間：2018-08-02 15:26
【摘要】：目的采用消風(fēng)散加減方聯(lián)合依巴斯汀治療風(fēng)熱犯表型蕁麻疹,綜合評價(jià)其治療蕁麻疹的癥狀完全消退時(shí)間、瘙癢改善情況、風(fēng)團(tuán)數(shù)目改善情況、生活質(zhì)量改善情況、疾病療效、不良反應(yīng)及復(fù)發(fā)率,分析其治療蕁麻疹的優(yōu)勢,探討中西醫(yī)結(jié)合療法的治療效果。方法將63例符合風(fēng)熱犯表型蕁麻疹患者按隨機(jī)數(shù)字表法分為治療組和對照組,治療組32例,采用口服消風(fēng)散加減方聯(lián)合依巴斯汀的方法;對照組31例,采用口服依巴斯汀方法。兩組療程均為兩周,分別在治療7天后、治療14天后各觀察1次療效,共觀察2次。比較兩組治療前后蕁麻疹活動(dòng)度(UAS)評分、皮膚病生活質(zhì)量(DLQI)評分、同時(shí)比較兩組患者的蕁麻疹癥狀完全消退時(shí)間、瘙癢改善情況、風(fēng)團(tuán)數(shù)目改善情況、疾病療效,并注意觀察治療過程中的不良反應(yīng)以及治療結(jié)束后1個(gè)月及3個(gè)月內(nèi)蕁麻疹患者的復(fù)發(fā)率。得出的所有數(shù)據(jù)均采用SPSS18.0軟件進(jìn)行統(tǒng)計(jì)學(xué)分析。結(jié)果(1)兩組治療前蕁麻疹活動(dòng)度(UAS)評分、風(fēng)團(tuán)數(shù)目評分、瘙癢癥狀評分、皮膚病生活質(zhì)量(DLQI)評分的組間比較均無統(tǒng)計(jì)學(xué)意義(P0.05),治療組和對照組在分別治療7天后、14天后與各自治療前相比,有顯著性差異(P0.01);其中,治療組和對照組在蕁麻疹活動(dòng)度(UAS)評分、風(fēng)團(tuán)數(shù)目評分、瘙癢癥狀評分、皮膚病生活質(zhì)量評分、疾病療效方面,治療14天后與治療7天的組內(nèi)比較,均有統(tǒng)計(jì)學(xué)意義(P0.05)。(2)兩組患者治療7天后蕁麻疹活動(dòng)度(UAS)評分、皮膚病生活質(zhì)量(DLQI)評分的組間比較差異無統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者治療7天后療效比較無統(tǒng)計(jì)學(xué)意義(P0.05)。(3)兩組患者治療14天后瘙癢癥狀評分、風(fēng)團(tuán)數(shù)目評分、蕁麻疹活動(dòng)度(UAS)評分、皮膚病生活質(zhì)量(DLQI)評分的組間比較均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者治療14天后療效比較有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組在改善患者的瘙癢癥狀、風(fēng)團(tuán)數(shù)目、DLQI評分、UAS評分、療效等方面均優(yōu)于對照組。(4)兩組蕁麻疹患者癥狀完全消退時(shí)間相比較:治療組蕁麻疹患者癥狀完全消退的平均時(shí)間為6.96±2.90天,對照組蕁麻疹患者癥狀完全消退的平均時(shí)間為8.95±3.73天;兩者相比差異有統(tǒng)計(jì)學(xué)意義(P0.05)。這表明治療組在快速改善蕁麻疹癥狀所用時(shí)間方面,要優(yōu)于對照組。(5)兩組患者治療過程中的不良反應(yīng)分布情況比較無明顯差異(P0.05)。(6)兩組患者治療后1個(gè)月內(nèi)的復(fù)發(fā)率比較無統(tǒng)計(jì)學(xué)意義(P0.05);治療后3個(gè)月內(nèi)的復(fù)發(fā)率比較無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論消風(fēng)散加減方聯(lián)合依巴斯汀治療風(fēng)熱犯表型蕁麻疹療效確切,在快速改善蕁麻疹患者瘙癢、消退風(fēng)團(tuán)數(shù)目、提高生活質(zhì)量等方面均優(yōu)于依巴斯汀組,復(fù)發(fā)率低且無明顯不良反應(yīng),值得臨床進(jìn)一步推廣應(yīng)用。
[Abstract]:Objective to treat phenotypic urticaria with Xiaofeng Powder and Ebustine, and to evaluate the time of complete regression, the improvement of pruritus, the improvement of the number of wind mass, the improvement of quality of life and the curative effect of the disease in the treatment of urticaria. Adverse reaction and recurrence rate, analysis of its advantages in the treatment of urticaria, explore the therapeutic effect of integrated Chinese and western medicine therapy. Methods Sixty-three patients with urticaria according to phenotype of rheumatic fever were randomly divided into two groups: treatment group (n = 32) and control group (n = 31). The course of treatment in both groups was two weeks. After 7 days and 14 days, the curative effect was observed once and twice respectively. Before and after treatment, the (UAS) score of urticaria activity, the (DLQI) score of quality of life of skin diseases, the time of complete regression of urticaria symptoms, the improvement of pruritus, the improvement of the number of wind masses, and the curative effect of the disease were compared between the two groups. The adverse reactions during treatment and the recurrence rate of urticaria patients within 1 month and 3 months after treatment were observed. All the obtained data were statistically analyzed by SPSS18.0 software. Results (1) before treatment, (UAS) score, wind mass number score, pruritus symptom score were used in the two groups. There was no significant difference in (DLQI) score of skin diseases between the two groups (P0.05). There was a significant difference between the treatment group and the control group after 7 days of treatment and 14 days after treatment compared with that before treatment (P0.01). In the treatment group and the control group, the (UAS) score of urticaria activity, the score of wind mass number, the score of pruritus symptom, the score of quality of life of skin disease, and the curative effect of the disease were compared between the treatment group and the control group after 14 days of treatment and 7 days of treatment. There was significant difference (P0.05). (2) between the two groups after 7 days of treatment of urticaria activity (UAS) score, There was no significant difference in (DLQI) score of skin disease quality of life between the two groups (P0.05), and there was no significant difference in curative effect between the two groups after 7 days of treatment (P0.05). (3). The score of pruritus symptom, the number of wind mass, the (UAS) score of urticaria activity after 14 days of treatment were not statistically significant between the two groups (P0.05). The (DLQI) score of dermatosis quality of life was statistically significant (P0.05). Two groups of patients after 14 days treatment efficacy was statistically significant (P0.05). In the treatment group, the symptoms of pruritus and the number of wind masses were improved by DLQI score and UAS score. (4) the mean time of complete disappearance of symptoms in the treatment group was 6.96 鹵2.90 days, and that in the control group was 8.95 鹵3.73 days. The difference was statistically significant (P0.05). This suggests that the treatment group took time to quickly improve the symptoms of urticaria. (5) there was no significant difference in the distribution of adverse reactions between the two groups in the course of treatment (P0.05). (6). There was no significant difference in the recurrence rate within one month after treatment between the two groups (P0.05); the recurrence rate within 3 months after treatment had no statistical significance (P0.05). Conclusion the curative effect of Xiaofengsan plus subtractive prescription combined with Ebastine in the treatment of phenotypic urticaria of rheumatic fever is effective. It is superior to Ebastine group in rapidly improving the pruritus, reducing the number of wind masses and improving the quality of life in patients with urticaria. The recurrence rate is low and there is no obvious adverse reaction, which is worthy of further clinical application.
【學(xué)位授予單位】：安徽中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R758.24
本文編號(hào)：2159867
[Abstract]:Objective to treat phenotypic urticaria with Xiaofeng Powder and Ebustine, and to evaluate the time of complete regression, the improvement of pruritus, the improvement of the number of wind mass, the improvement of quality of life and the curative effect of the disease in the treatment of urticaria. Adverse reaction and recurrence rate, analysis of its advantages in the treatment of urticaria, explore the therapeutic effect of integrated Chinese and western medicine therapy. Methods Sixty-three patients with urticaria according to phenotype of rheumatic fever were randomly divided into two groups: treatment group (n = 32) and control group (n = 31). The course of treatment in both groups was two weeks. After 7 days and 14 days, the curative effect was observed once and twice respectively. Before and after treatment, the (UAS) score of urticaria activity, the (DLQI) score of quality of life of skin diseases, the time of complete regression of urticaria symptoms, the improvement of pruritus, the improvement of the number of wind masses, and the curative effect of the disease were compared between the two groups. The adverse reactions during treatment and the recurrence rate of urticaria patients within 1 month and 3 months after treatment were observed. All the obtained data were statistically analyzed by SPSS18.0 software. Results (1) before treatment, (UAS) score, wind mass number score, pruritus symptom score were used in the two groups. There was no significant difference in (DLQI) score of skin diseases between the two groups (P0.05). There was a significant difference between the treatment group and the control group after 7 days of treatment and 14 days after treatment compared with that before treatment (P0.01). In the treatment group and the control group, the (UAS) score of urticaria activity, the score of wind mass number, the score of pruritus symptom, the score of quality of life of skin disease, and the curative effect of the disease were compared between the treatment group and the control group after 14 days of treatment and 7 days of treatment. There was significant difference (P0.05). (2) between the two groups after 7 days of treatment of urticaria activity (UAS) score, There was no significant difference in (DLQI) score of skin disease quality of life between the two groups (P0.05), and there was no significant difference in curative effect between the two groups after 7 days of treatment (P0.05). (3). The score of pruritus symptom, the number of wind mass, the (UAS) score of urticaria activity after 14 days of treatment were not statistically significant between the two groups (P0.05). The (DLQI) score of dermatosis quality of life was statistically significant (P0.05). Two groups of patients after 14 days treatment efficacy was statistically significant (P0.05). In the treatment group, the symptoms of pruritus and the number of wind masses were improved by DLQI score and UAS score. (4) the mean time of complete disappearance of symptoms in the treatment group was 6.96 鹵2.90 days, and that in the control group was 8.95 鹵3.73 days. The difference was statistically significant (P0.05). This suggests that the treatment group took time to quickly improve the symptoms of urticaria. (5) there was no significant difference in the distribution of adverse reactions between the two groups in the course of treatment (P0.05). (6). There was no significant difference in the recurrence rate within one month after treatment between the two groups (P0.05); the recurrence rate within 3 months after treatment had no statistical significance (P0.05). Conclusion the curative effect of Xiaofengsan plus subtractive prescription combined with Ebastine in the treatment of phenotypic urticaria of rheumatic fever is effective. It is superior to Ebastine group in rapidly improving the pruritus, reducing the number of wind masses and improving the quality of life in patients with urticaria. The recurrence rate is low and there is no obvious adverse reaction, which is worthy of further clinical application.
【學(xué)位授予單位】：安徽中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R758.24
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 溫炬;陳寶田;李慧;林中方;阮一民;馬靜;馮潔瑩;;消風(fēng)散對Ⅰ型變態(tài)反應(yīng)的實(shí)驗(yàn)研究[J];南方醫(yī)科大學(xué)學(xué)報(bào);2009年11期
2 溫炬;陳寶田;蘭海梅;李慧;林中方;阮一民;馬靜;馮潔瑩;;消風(fēng)散抗炎活性的動(dòng)物實(shí)驗(yàn)研究[J];廣東醫(yī)學(xué);2009年12期
3 賀學(xué)榮;何川;龔建平;;肥大細(xì)胞激活機(jī)制與變態(tài)反應(yīng)性疾病關(guān)系的研究進(jìn)展[J];重慶醫(yī)學(xué);2014年09期
4 曾黎峰;錢金榮;;慢性蕁麻疹過敏原檢測的結(jié)果分析[J];實(shí)驗(yàn)與檢驗(yàn)醫(yī)學(xué);2011年06期
5 吳伊旋;沈惠風(fēng);;慢性蕁麻疹部分發(fā)病機(jī)制的研究進(jìn)展[J];臨床皮膚科雜志;2008年02期
6 周萍;卡介菌多糖核酸用于慢性蕁麻疹治療的效果觀察[J];現(xiàn)代實(shí)用醫(yī)學(xué);2005年07期
7 鄒維宇;向亞君;吳興立;廖品東;;廖品東運(yùn)用小兒推拿治療小兒蕁麻疹臨床經(jīng)驗(yàn)[J];湖北中醫(yī)雜志;2014年02期
8 任曉麗;蘇振興;劉宏業(yè);白莉;;幽門螺桿菌感染與慢性蕁麻疹相關(guān)關(guān)系的臨床觀察[J];實(shí)用皮膚病學(xué)雜志;2012年06期
9 曾憲斌;馮林;;消風(fēng)散顆粒對肥大細(xì)胞脫顆粒的抑制作用[J];江西中醫(yī)學(xué)院學(xué)報(bào);2008年01期
10 唐春蕾,劉新國,劉麗君;針刺治療慢性蕁麻疹80例[J];中國針灸;2005年04期
，本文編號(hào)：2159867
本文鏈接：http://sikaile.net/yixuelunwen/pifb/2159867.html
最近更新
教材專著
